Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.64 Analyst target: $1.25 Upside: 94.16%
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.